RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Blueprint Medicines Stock

Blueprint Medicines P/S 2025

Blueprint Medicines P/S

10.96

Ticker

BPMC

ISIN

US09627Y1091

WKN

A14SDD

As of Jun 21, 2025, Blueprint Medicines's P/S ratio stood at 10.96, a 1.76% change from the 10.77 P/S ratio recorded in the previous year.

The Blueprint Medicines P/S history

Blueprint Medicines Aktienanalyse

What does Blueprint Medicines do?

Blueprint Medicines Corp is a biotechnology company that focuses on the discovery, development, and commercialization of drugs for the treatment of genetic diseases. The company was founded in 2008 by a team of experts in the field of molecular biology, biochemistry, and cancer research and is headquartered in Cambridge, Massachusetts, USA. History Blueprint Medicines started as a spin-off from the Broad Institute of MIT and Harvard, a partnership between the Massachusetts Institute of Technology and Harvard University. The founders' goal was to develop a new type of drugs based on the genetic cause of diseases, rather than just treating symptoms. In 2016, the company went public and has since experienced rapid growth. Blueprint Medicines has generated significant revenue through the sale of its products as well as through licensing agreements with other companies. Business model Blueprint Medicines aims to play a leading role in the development of novel drugs based on the identification and treatment of gene mutations. The company utilizes a combination of computer technology, molecular biology, chemistry, and clinical research to specifically target the causes of diseases. Blueprint Medicines has three main areas of focus: 1. Oncology The main focus of Blueprint Medicines is cancer research. The company has several drugs in development that specifically target mutations associated with certain types of cancer. These drugs aim to improve the effectiveness of cancer treatment and enhance patients' quality of life. 2. Blue Flag Technology Blueprint Medicines has developed a proprietary technology called Blue Flag, which allows the company to rapidly and accurately identify and characterize specific mutations in genes. This technology is key to the development of precision medicine approaches tailored to the specific needs of patients. 3. Rare diseases Blueprint Medicines also has a commitment to developing drugs for the treatment of rare diseases. The company collaborates with patients, physicians, and patient organizations to develop drugs that meet the needs of patients with rare diseases. Products Blueprint Medicines has brought several products to market and is working on developing additional products. Here are some of the key products: 1. Ayvakit Ayvakit is a drug for the treatment of gastrointestinal stromal tumors (GIST) associated with a specific genetic mutation. The drug has proven to be highly effective and has been approved by the U.S. Food and Drug Administration (FDA). 2. Gavreto Gavreto is a drug for the treatment of adult patients with a specific genetic mutation associated with non-small cell lung cancer. The drug is being developed in collaboration with pharmaceutical company Roche. 3. Pralsetinib Pralsetinib is a drug for the treatment of patients with a specific gene mutation associated with thyroid cancer. The drug has proven to be highly effective and has been approved by the U.S. FDA. Conclusion Blueprint Medicines Corp is an emerging biotechnology company that focuses on the discovery, development, and commercialization of drugs for the treatment of genetic diseases. The company has established itself as a leader in the field of personalized medicine and has brought several highly effective products to market. Blueprint Medicines continues to work on developing innovative treatment methods for rare diseases and aims to solidify its position as a leading provider of personalized drugs in the global healthcare market. Blueprint Medicines ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Blueprint Medicines's P/S Ratio

Blueprint Medicines's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Blueprint Medicines's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Blueprint Medicines's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Blueprint Medicines’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Blueprint Medicines stock

What is the price-to-earnings ratio of Blueprint Medicines?

The price-earnings ratio of Blueprint Medicines is currently 10.96.

How has the price-earnings ratio of Blueprint Medicines changed compared to last year?

The price-to-earnings ratio of Blueprint Medicines has increased by 1.76% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Blueprint Medicines high compared to other companies?

Yes, the price-to-earnings ratio of Blueprint Medicines is high compared to other companies.

How does an increase in the price-earnings ratio of Blueprint Medicines affect the company?

An increase in the price-earnings ratio of Blueprint Medicines would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Blueprint Medicines affect the company?

A decrease in the price-earnings ratio of Blueprint Medicines would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Blueprint Medicines?

Some factors that influence the price-earnings ratio of Blueprint Medicines are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Blueprint Medicines pay?

Over the past 12 months, Blueprint Medicines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Blueprint Medicines is expected to pay a dividend of 0 USD.

What is the dividend yield of Blueprint Medicines?

The current dividend yield of Blueprint Medicines is .

When does Blueprint Medicines pay dividends?

Blueprint Medicines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Blueprint Medicines?

Blueprint Medicines paid dividends every year for the past 0 years.

What is the dividend of Blueprint Medicines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Blueprint Medicines located?

Blueprint Medicines is assigned to the 'Health' sector.

Wann musste ich die Aktien von Blueprint Medicines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Blueprint Medicines from 6/21/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/21/2025.

When did Blueprint Medicines pay the last dividend?

The last dividend was paid out on 6/21/2025.

What was the dividend of Blueprint Medicines in the year 2024?

In the year 2024, Blueprint Medicines distributed 0 USD as dividends.

In which currency does Blueprint Medicines pay out the dividend?

The dividends of Blueprint Medicines are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Blueprint Medicines stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Blueprint Medicines

Our stock analysis for Blueprint Medicines Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Blueprint Medicines Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.